Supernus (SUPN) EBITDA Margin (2022 - 2026)
Supernus Pharmaceuticals (SUPN) recorded EBITDA Margin of 19.76% in Q3 2026, up 38.20 percentage points from -18.44% a year earlier and up 34.46 percentage points from the prior quarter.
Powered by 
Analysis
Supernus (SUPN) EBITDA Margin (2022 - 2026) Analysis & Trends
On a TTM basis, Supernus Pharmaceuticals' EBITDA Margin came in at -0.21% as of Sep 30, 2026, down 7.32 percentage points year-over-year; for FY2025, it was 4.07%, down 20.42 percentage points from FY2024.
- Annual EBITDA Margin has a five-year change of -35.98 percentage points (FY2020 to FY2025).
- Across earlier years, EBITDA Margin came in at 24.49% in FY2024 (+11.30 pp), 13.19% in FY2023 (-6.86 pp), 20.05% in FY2022 (-3.43 pp) and 23.48% in FY2021 (-16.57 pp).
- The Q3 2026 figure is the highest quarterly EBITDA Margin since Q2 2025.
- On a year-over-year basis, EBITDA Margin rose in two of the last seven quarters, with an average year-over-year change of -9.07 percentage points.
- Peak year-over-year performance for EBITDA Margin in the last five years was a gain of 38.20 percentage points in Q3 2026, against a drop of 53.13 percentage points in Q3 2025 at the low end.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 36.69% |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 32.68% |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 46.88% |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 40.60% |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 39.77% |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 46.62% |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | 50.63% |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 42.49% |
| 10 | Supernus | 3.39 Bn | 2.50 Bn | 305.00 Mn | 50.84% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 50.84% |
| Jun 30, 2026 | 47.23% |
| Mar 31, 2026 | 43.85% |
| Dec 31, 2025 | 23.18% |
| Sep 30, 2025 | 14.65% |
| Jun 30, 2025 | 24.50% |
| Mar 31, 2025 | 25.94% |
| Dec 31, 2024 | 17.06% |
| Sep 30, 2024 | 12.70% |
| Jun 30, 2024 | -38.80% |
| Mar 31, 2024 | 28.17% |
| Dec 31, 2023 | 21.16% |
| Sep 30, 2023 | -65.31% |
| Jun 30, 2023 | 23.19% |
| Mar 31, 2023 | 24.11% |
| Dec 31, 2022 | -104.98% |
| Sep 30, 2022 | 25.86% |
API Access
Supernus EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=SUPN&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "SUPN", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=SUPN&period=max&api_key=YOUR_API_KEY");
const data = await res.json();